XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO(TM), Targeting USD$700M+ U.S. Gout Market Opportunity

Stock Information for XORTX Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About XORTX Therapeutics Inc.

XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO(TM)
XORTX Re-Engages Investor Relations Program
XORTX Announces Termination and Postponement of Investor Relations Program
XORTX Announces Director Resignation
XORTX Appoints New Director
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.